Cepheid Gains IVDR CE Mark for Respiratory Panel
Sunnyvale, California, United States, November 10, 2026 Cepheid, a Danaher company specializing in molecular diagnostics, has achieved CE marking...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Sunnyvale, California, United States, November 10, 2026 Cepheid, a Danaher company specializing in molecular diagnostics, has achieved CE marking...
León, Spain, November 9, 2026 Curia Global, Inc., a global contract research, development and manufacturing organization (CDMO), has announced...
Ingelheim am Rhein, Germany, November 10, 2026 Boehringer Ingelheim has announced that the European Medicines Agency’s Committee for Veterinary...
Cambridge, Massachusetts, United States, November 9, 2026 Alnylam Pharmaceuticals, Inc. has announced encouraging five-year clinical findings from its HELIOS-B...
Dover, Delaware, United States, November 9, 2026 Eilean Therapeutics, LLC, a clinical-stage biotechnology company developing targeted protein degraders, has...
Annapolis, Maryland, United States, November 9, 2026 Alphyn Biologics, Inc., a clinical-stage dermatology company, has announced the publication of...
Misgav, Israel, November 9, 2026 Biond Biologics Ltd., a clinical-stage biotechnology company developing innovative immunotherapies, has announced that the...
Boston, Massachusetts, United States, November 9, 2026 HotSpot Therapeutics, Inc., a biotechnology company developing innovative oral medicines, has announced...
Carmiel, Israel, November 9, 2026 Protalix BioTherapeutics, Inc. has announced encouraging new clinical findings for PRX-115, an investigational recombinant...
Castres, France, and Shenzhen, China, November 9, 2026 Pierre Fabre Laboratories and XtalPi Holdings Limited have announced a strategic...
